Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma.
NNMT
NNMTi
glutamine
metabolism
metastasis
oxphos
renal cell carcinoma
Journal
Clinical and translational medicine
ISSN: 2001-1326
Titre abrégé: Clin Transl Med
Pays: United States
ID NLM: 101597971
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
27
04
2022
received:
30
04
2021
accepted:
03
05
2022
entrez:
9
6
2022
pubmed:
10
6
2022
medline:
11
6
2022
Statut:
ppublish
Résumé
The metabolic enzyme nicotinamide-N-methyltransferase (NNMT) is highly expressed in various cancer entities, suggesting tumour-promoting functions. We systematically investigated NNMT expression and its metabolic interactions in clear cell renal cell carcinoma (ccRCC), a prominent RCC subtype with metabolic alterations, to elucidate its role as a drug target. NNMT expression was assessed in primary ccRCC (n = 134), non-tumour tissue and ccRCC-derived metastases (n = 145) by microarray analysis and/or immunohistochemistry. Findings were validated in The Cancer Genome Atlas (kidney renal clear cell carcinoma [KIRC], n = 452) and by single-cell analysis. Expression was correlated with clinicopathological data and survival. Metabolic alterations in NNMT-depleted cells were assessed by nontargeted/targeted metabolomics and extracellular flux analysis. The NNMT inhibitor (NNMTi) alone and in combination with the inhibitor 2-deoxy-D-glucose for glycolysis and BPTES (bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl-sulfide) for glutamine metabolism was investigated in RCC cell lines (786-O, A498) and in two 2D ccRCC-derived primary cultures and three 3D ccRCC air-liquid interface models. NNMT protein was overexpressed in primary ccRCC (p = 1.32 × 10 Since efficient glutamine utilisation, which is essential for ccRCC tumours, depends on NNMT, small-molecule NNMT inhibitors provide a novel therapeutic strategy for ccRCC and act as sensitizers for combination therapies.
Sections du résumé
BACKGROUND
The metabolic enzyme nicotinamide-N-methyltransferase (NNMT) is highly expressed in various cancer entities, suggesting tumour-promoting functions. We systematically investigated NNMT expression and its metabolic interactions in clear cell renal cell carcinoma (ccRCC), a prominent RCC subtype with metabolic alterations, to elucidate its role as a drug target.
METHODS
NNMT expression was assessed in primary ccRCC (n = 134), non-tumour tissue and ccRCC-derived metastases (n = 145) by microarray analysis and/or immunohistochemistry. Findings were validated in The Cancer Genome Atlas (kidney renal clear cell carcinoma [KIRC], n = 452) and by single-cell analysis. Expression was correlated with clinicopathological data and survival. Metabolic alterations in NNMT-depleted cells were assessed by nontargeted/targeted metabolomics and extracellular flux analysis. The NNMT inhibitor (NNMTi) alone and in combination with the inhibitor 2-deoxy-D-glucose for glycolysis and BPTES (bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl-sulfide) for glutamine metabolism was investigated in RCC cell lines (786-O, A498) and in two 2D ccRCC-derived primary cultures and three 3D ccRCC air-liquid interface models.
RESULTS
NNMT protein was overexpressed in primary ccRCC (p = 1.32 × 10
CONCLUSIONS
Since efficient glutamine utilisation, which is essential for ccRCC tumours, depends on NNMT, small-molecule NNMT inhibitors provide a novel therapeutic strategy for ccRCC and act as sensitizers for combination therapies.
Identifiants
pubmed: 35678045
doi: 10.1002/ctm2.883
pmc: PMC9178377
doi:
Substances chimiques
Glutamine
0RH81L854J
Niacinamide
25X51I8RD4
Deoxyglucose
9G2MP84A8W
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e883Informations de copyright
© 2022 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
Références
Cell Metab. 2018 Nov 6;28(5):706-720.e6
pubmed: 30122555
Eur Urol. 2015 Dec;68(6):1016-20
pubmed: 26072688
Oncotarget. 2017 Apr 18;8(16):26200-26220
pubmed: 28412735
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Oncogene. 2008 Nov 6;27(52):6679-89
pubmed: 18724390
Cell. 2015 Jul 30;162(3):540-51
pubmed: 26232224
Drug Discov Today. 2021 Nov;26(11):2699-2706
pubmed: 34029690
Cell Physiol Biochem. 2015;35(2):710-21
pubmed: 25592232
Cell Metab. 2013 Mar 5;17(3):372-85
pubmed: 23473032
Nucleic Acids Res. 2013 Apr;41(8):4378-91
pubmed: 23444143
Clin Cancer Res. 2017 May 1;23(9):2325-2334
pubmed: 27810903
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Anal Chem. 2013 Jul 16;85(14):6876-84
pubmed: 23781873
Nat Rev Nephrol. 2017 Jul;13(7):410-419
pubmed: 28480903
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
Oncogenesis. 2018 Aug 10;7(8):58
pubmed: 30093610
Genomics. 2012 Dec;100(6):337-44
pubmed: 22959562
J Cancer Res Clin Oncol. 2008 May;134(5):551-9
pubmed: 17922140
Oncotarget. 2016 Jul 19;7(29):45837-45848
pubmed: 27323852
Sci Rep. 2016 Jul 20;6:29930
pubmed: 27435027
Cell Mol Biol (Noisy-le-grand). 2018 May 30;64(7):51-55
pubmed: 29974846
Nucleic Acids Res. 2005 Nov 10;33(20):e175
pubmed: 16284200
Biochem Pharmacol. 2019 May;163:481-492
pubmed: 30753815
Mol Carcinog. 2020 Aug;59(8):940-954
pubmed: 32367570
BMC Med. 2013 Apr 16;11:106
pubmed: 23590835
Metabolites. 2020 Dec 01;10(12):
pubmed: 33271860
Biochem Pharmacol. 2018 Jan;147:141-152
pubmed: 29155147
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Carcinogenesis. 2011 Feb;32(2):138-45
pubmed: 21045016
Arch Biochem Biophys. 2014 Dec 15;564:52-66
pubmed: 25201588
Genome Med. 2020 Mar 30;12(1):32
pubmed: 32228647
Mol Cell Oncol. 2019 Jul 9;6(5):e1536843
pubmed: 31528687
Metabolomics. 2014;10(5):909-919
pubmed: 25177232
Anticancer Res. 2018 Jan;38(1):187-197
pubmed: 29277772
Sci Rep. 2021 Mar 11;11(1):5637
pubmed: 33707534
Biotechnol Bioeng. 2008 Jun 1;100(2):344-54
pubmed: 18095337
J Proteome Res. 2017 Feb 3;16(2):933-944
pubmed: 27992229
Cancer Res. 1984 Aug;44(8):3522-9
pubmed: 6744277
J Pathol. 2005 Feb;205(3):377-87
pubmed: 15682440
Cancer Res. 2017 Dec 1;77(23):6746-6758
pubmed: 29021138
Sci Rep. 2018 Feb 26;8(1):3660
pubmed: 29483571
J Clin Invest. 2017 May 1;127(5):1631-1645
pubmed: 28346230
Sci Rep. 2015 Jun 04;5:10738
pubmed: 26040780
Cancer Res. 2012 Nov 1;72(21):5494-504
pubmed: 22942254
Biochem J. 2011 May 15;436(1):145-55
pubmed: 21352099
JCI Insight. 2017 May 18;2(10):
pubmed: 28515364
Eur Urol. 2021 Mar;79(3):339-342
pubmed: 33357997
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Cancer Res. 2015 Jun 15;75(12):2541-52
pubmed: 25952651
Nat Rev Mol Cell Biol. 2020 Oct;21(10):571-584
pubmed: 32636524
Cancer Cell Int. 2020 May 24;20:191
pubmed: 32489327
Nat Chem Biol. 2013 May;9(5):300-6
pubmed: 23455543
Metab Eng. 2009 Jul-Sep;11(4-5):292-309
pubmed: 19555774
Front Physiol. 2018 Oct 08;9:1407
pubmed: 30349486
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):E866-75
pubmed: 24550497
Mol Cancer. 2016 Dec 19;15(1):83
pubmed: 27993170
Nature. 2014 Apr 10;508(7495):258-62
pubmed: 24717514
Front Oncol. 2020 Sep 22;10:1775
pubmed: 33072556
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Sci Adv. 2021 Jan 20;7(4):
pubmed: 33523930
Cell. 2015 Jul 30;162(3):552-63
pubmed: 26232225
Biochem Biophys Res Commun. 2015 Nov 20;467(3):491-6
pubmed: 26456643
Cell. 2018 Dec 13;175(7):1972-1988.e16
pubmed: 30550791
Int J Tryptophan Res. 2017 Jun 30;10:1178646917691739
pubmed: 35185340
J Urol. 2006 Nov;176(5):2248-54
pubmed: 17070307
Radiother Oncol. 2011 Jun;99(3):373-8
pubmed: 21719135
Science. 2018 Aug 10;361(6402):594-599
pubmed: 30093597
Mol Endocrinol. 2005 Feb;19(2):527-39
pubmed: 15486044
Clin Transl Med. 2022 Jun;12(6):e883
pubmed: 35678045
Nature. 2019 May;569(7758):723-728
pubmed: 31043742
Eur Urol Focus. 2019 Jul;5(4):608-618
pubmed: 29452772
BJU Int. 2012 May;109(10):1565-70
pubmed: 21981759
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484